- Home
- AGIO vs CNOB Comparison
AGIO vs CNOB Comparison
Compare AGIO & CNOB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AGIO | CNOB |
|---|---|---|
| Founded | 2007 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | 2013 | 1996 |
Fundamental Metrics
Financial Performance| Metric | AGIO | CNOB |
|---|---|---|
| Price | $27.95 | $27.64 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 2 |
| Target Price | ★ $36.63 | $30.00 |
| AVG Volume (30 Days) | ★ 881.5K | 297.5K |
| Earning Date | 02-12-2026 | 01-29-2026 |
| Dividend Yield | N/A | ★ 2.59% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.63 |
| Revenue | $54,028,000.00 | ★ $341,316,000.00 |
| Revenue This Year | $104.62 | $38.80 |
| Revenue Next Year | $125.15 | $7.49 |
| P/E Ratio | ★ N/A | $17.02 |
| Revenue Growth | ★ 48.03 | 36.38 |
| 52 Week Low | $22.24 | $20.61 |
| 52 Week High | $46.00 | $29.28 |
Technical Indicators
Market Signals| Indicator | AGIO | CNOB |
|---|---|---|
| Relative Strength Index (RSI) | 54.94 | 47.14 |
| Support Level | $26.05 | $27.37 |
| Resistance Level | $29.93 | $28.79 |
| Average True Range (ATR) | 1.18 | 0.85 |
| MACD | 0.10 | -0.10 |
| Stochastic Oscillator | 62.47 | 35.99 |
Price Performance
Historical ComparisonAbout AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
About CNOB ConnectOne Bancorp Inc.
ConnectOne Bancorp Inc is a community-based, full-service New Jersey-chartered commercial bank. Substantially all loans are secured with various types of collateral, including business assets, consumer assets and commercial/residential real estate. Each borrower's ability to repay its loans is dependent on the conversion of assets, cash flows generated from the borrowers' business, real estate rental and consumer wages.